Trial
NCT06299761
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boundless Bio, Inc.
Collaborators
—
Condition
Solid Tumor
Intervention
BBI-825
Why stopped
Strategic decision made following an assessment of preliminary PK data from the Part 1 portion of the trial showing a lack of dose proportional exposure and the increasing complexity and associated development costs in this landscape.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08